These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15939704)

  • 1. A risk assessment perspective: application of mode of action and human relevance frameworks to the analysis of rodent tumor data.
    Dellarco VL; Baetcke K
    Toxicol Sci; 2005 Jul; 86(1):1-3. PubMed ID: 15939704
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the human relevance of chemically induced animal tumors.
    Cohen SM; Klaunig J; Meek ME; Hill RN; Pastoor T; Lehman-McKeeman L; Bucher J; Longfellow DG; Seed J; Dellarco V; Fenner-Crisp P; Patton D
    Toxicol Sci; 2004 Apr; 78(2):181-6. PubMed ID: 14737005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IPCS framework for analyzing the relevance of a cancer mode of action for humans.
    Boobis AR; Cohen SM; Dellarco V; McGregor D; Meek ME; Vickers C; Willcocks D; Farland W
    Crit Rev Toxicol; 2006; 36(10):781-92. PubMed ID: 17118728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals.
    Meek ME
    Environ Mol Mutagen; 2008 Mar; 49(2):110-6. PubMed ID: 18213650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment.
    Proctor DM; Gatto NM; Hong SJ; Allamneni KP
    Toxicol Sci; 2007 Aug; 98(2):313-26. PubMed ID: 17426108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decision tree approach for carcinogen risk assessment.
    Butterworth BE; Eldridge SR
    Prog Clin Biol Res; 1995; 391():49-70. PubMed ID: 8532737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
    Butterworth BE
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the application of data on mode of action to carcinogenic risk assessment.
    Rice JM
    Toxicol Sci; 2004 Apr; 78(2):175-7. PubMed ID: 15014206
    [No Abstract]   [Full Text] [Related]  

  • 9. Cancer risk assessment at the crossroads: the need to turn to a biological approach.
    Clayson DB; Iverson F
    Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 1):45-59. PubMed ID: 8921545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of in vivo mutation data can inform cancer risk assessment.
    Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform.
    Liao KH; Tan YM; Conolly RB; Borghoff SJ; Gargas ML; Andersen ME; Clewell HJ
    Risk Anal; 2007 Dec; 27(6):1535-51. PubMed ID: 18093051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of human carcinogens.
    Ashby J; Morrod RS
    Nature; 1991 Jul; 352(6332):185-6. PubMed ID: 1857407
    [No Abstract]   [Full Text] [Related]  

  • 14. Application of mode-of-action considerations in human cancer risk assessment.
    Williams GM
    Toxicol Lett; 2008 Aug; 180(2):75-80. PubMed ID: 18588958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
    McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
    Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action in relevance of rodent liver tumors to human cancer risk.
    Holsapple MP; Pitot HC; Cohen SM; Boobis AR; Klaunig JE; Pastoor T; Dellarco VL; Dragan YP
    Toxicol Sci; 2006 Jan; 89(1):51-6. PubMed ID: 16221960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe.
    Van Oosterhout JP; Van der Laan JW; De Waal EJ; Olejniczak K; Hilgenfeld M; Schmidt V; Bass R
    Regul Toxicol Pharmacol; 1997 Feb; 25(1):6-17. PubMed ID: 9056497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk assessment of carcinogens in Japan.
    Hayashi Y
    Exp Toxicol Pathol; 1996 Feb; 48(2-3):197. PubMed ID: 8672875
    [No Abstract]   [Full Text] [Related]  

  • 19. How valuable the dog in the routine testing of suspected carcinogens?
    Bonser GM
    J Natl Cancer Inst; 1969 Jul; 43(1):271-4. PubMed ID: 5796389
    [No Abstract]   [Full Text] [Related]  

  • 20. IPCS framework for analyzing the relevance of a noncancer mode of action for humans.
    Boobis AR; Doe JE; Heinrich-Hirsch B; Meek ME; Munn S; Ruchirawat M; Schlatter J; Seed J; Vickers C
    Crit Rev Toxicol; 2008; 38(2):87-96. PubMed ID: 18259981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.